Gossamer Bio was named in symbolism of the Gossamer thread, the invisible and fragile connection that binds all relationships in life. Gossamer’s name was chosen to highlight the importance of the organization’s relationships with our partners, members of our community, and of course – patients. Recognizing there is no time to give less than our best, Gossamer’s commitment to the patient community is real – our team aims to improve patient lives through meaningful advances in the development of new therapies and an unwavering commitment to supporting patient communities across the globe.
At Gossamer Bio, we recognize that choosing to participate in a clinical study is a big decision, requiring both time & commitment, and the Gossamer Team extends our sincerest THANK YOU to all patients who have participated in a clinical trial – without your participation, advancements in research would not be possible!
Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial Hypertension (PAH) is a rare and chronic disease characterized by narrowing of the blood vessels in the lung, making it more difficult for blood to adequately flow from the heart to the lungs and disrupting one’s regular blood flow. This disruption prevents the lungs from receiving enough oxygen, putting extra strain on one’s heart, and making it harder to pump blood through the lungs and deliver oxygen.
Gossamer Bio is currently enrolling a Phase 2 clinical research study evaluating the safety and efficacy of Seralutinib (AKA GB002), an inhaled investigational therapy, in adults with Pulmonary Arterial Hypertension (PAH).
Every clinical research study is different. Below are more details about the TORREY Study. When considering joining a study, ask you doctor fo more information about what to expect.
- TORREY Study on clinicaltrials.gov
- 2021 PHPN Symposium Presentation
- GOSS-PHAware Podcast Episode #2
- Request More Information About TORREY